net income -$17.8M. Transcode adds two clinical programs via acquisition and licensing, extends cash runway to year-end 2026

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~2 min read

Key Changes

• high

  Acquired Polynoma for 12.4M-share-equivalent preferred stock, adding melanoma vaccine Seviprotimut-L and triggering up to $95M in milestone payments if FDA approval achieved; licensed preclinical adenovirus program from Unleash for 1.2M preferred shares.

  MD&A: Polynoma acquisition, Unleash licensing verify on EDGAR →
• high

  Phase I/II trial of lead asset TTX-MC138 met primary safety endpoint in 16 patients with no dose-limiting toxicities; patients remained on study 2-20 cycles. New 45-patient colorectal cancer trial via PRE-I-SPY collaboration planned for Q2 2026.

  MD&A: Phase I/II results, PRE-I-SPY collaboration verify on EDGAR →
• high

  Removed going-concern language and extended cash runway from Q4 2025 to year-end 2026 after raising $24.5M over 12 months; established up to $14M Yorkville equity facility and $6M convertible note facility.

  MD&A: Going concern removal, Yorkville financing verify on EDGAR →